Thirteen IPOs raised a combined $4.4 billion in February, joined by two direct listings. Deal flow started off strong but stumbled mid-month as concerns around AI disruption sparked a sell-off in tech stocks and recent listings, and heightened volatility led to ...read more
Generate Biomedicines, a Phase 3 biotech using AI to develop therapies for immunology and oncology, raised $400 million by offering 25 million shares at $16, the midpoint of the range of $15 to $17. Generate Biomedicines states that its AI-enabled Generate...read more
Generate Biomedicines, a Phase 3 biotech using an AI drug discovery platform to develop severe asthma therapies, announced terms for its IPO on Monday. The Somerville, MA-based company plans to raise $400 million by offering 25 million shares at a price range...read more
Updated Monday, 2/23. The typical February lull has taken hold of the IPO market while issuers work on year-end audited financials, but one sizable biotech is scheduled to go public before month end. Small deals may also join the calendar throughout the week. ...read more
Renaissance Capital's February IPO Market Update
Thirteen IPOs raised a combined $4.4 billion in February, joined by two direct listings. Deal flow started off strong but stumbled mid-month as concerns around AI disruption sparked a sell-off in tech stocks and recent listings, and heightened volatility led to ...read more
Asthma-focused AI biotech Generate Biomedicines prices IPO at $16 midpoint
Generate Biomedicines, a Phase 3 biotech using AI to develop therapies for immunology and oncology, raised $400 million by offering 25 million shares at $16, the midpoint of the range of $15 to $17. Generate Biomedicines states that its AI-enabled Generate...read more
Asthma-focused AI biotech Generate Biomedicines sets terms for $400 million IPO
Generate Biomedicines, a Phase 3 biotech using an AI drug discovery platform to develop severe asthma therapies, announced terms for its IPO on Monday. The Somerville, MA-based company plans to raise $400 million by offering 25 million shares at a price range...read more
US IPO Week Ahead: Asthma biotech set to close out February IPO market
Updated Monday, 2/23. The typical February lull has taken hold of the IPO market while issuers work on year-end audited financials, but one sizable biotech is scheduled to go public before month end. Small deals may also join the calendar throughout the week. ...read more